Overview

Somatostatin Receptor Imaging in Cardiac Sarcoidosis

Status:
Withdrawn
Trial end date:
2020-02-27
Target enrollment:
Participant gender:
Summary
The purpose of the trial is to determine the accuracy of Cu-64 labelled DOTATATE for diagnosing cardiac sarcoidosis using PET/CT or PET/MRI.
Details
Lead Sponsor:
Rigshospitalet, Denmark
Treatments:
Somatostatin